Clinical Trial Search

Phase 3 N=472 Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

Diabetes · Diabetes Mellitus, Type 1

Primary: Change in Glycosylated Haemoglobin (HbA1c) — 7.49; 7.49; -0.06; -0.14 Percentage (%) of HbA1c

Novo Nordisk A/S Results Jul 2018 2.8% serious AE View details

Phase 3 N=329 A Different Approach to Preventing Thrombosis

Venous Thromboembolism · Pulmonary Embolism

Primary: Number of Participants With Treatment-related Bleeding Events as Assessed by the Need for Blood Transfusions and Procedures for Bleeding Complications After Initiation…

University of Maryland, Baltimore Results Jul 2018 0.0% serious AE View details

Phase 3 N=60 Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Cystinosis

Primary: Number of Participants With Treatment-emergent Adverse Events — 58; 37; 24; 32 Participants

Amgen Results Jul 2018 54.2% serious AE View details

Phase 3 N=986 Open Label Study of Long Term Safety Evaluation of Alirocumab

Hypercholesterolemia

Primary: Percentage of Participants Who Experienced Adverse Events (AEs) — 83.9; 87.3; 86.2; 20.6 percentage of participants

Sanofi Results Jul 2018 21.5% serious AE View details

Phase 3 N=50 A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Breast Cancer

Primary: Percentage of Participants With Adverse Events (AEs) and Serious AEs — 100.0; 54.0 percentage of participants

Hoffmann-La Roche Results Jul 2018 54.0% serious AE View details

Phase 3 N=125 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Acromegaly

Primary: Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period — 57.9 percentage of subjects…

Ipsen Results Jul 2018 8.8% serious AE View details

Phase 3 N=20 Saizen® E-Device User Trial

Growth Disorders

Primary: Subjects' Overall Impression After Using E-Device — 0; 7; 13 subjects

Merck KGaA, Darmstadt, Germany Results Jul 2018 0.0% serious AE View details

Phase 3 N=295 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Virus · Hepatitis C Virus

Primary: Percentage of Participants in Arms A and B With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 99.1; 100 percentage of participants

AbbVie Results Jul 2018 1.4% serious AE View details

Phase 3 N=567 Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

HIV-1 Infection

Primary: Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm — 1.1; 0.4 percentage of…

Gilead Sciences Results Jul 2018 7.2% serious AE View details

Phase 3 N=631 Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Primary: Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm — 92.4; 93.0 percentage of participants…

Gilead Sciences Results Jul 2018 12.0% serious AE View details

Phase 3 N=326 Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

HIV Infections · Lipodystrophy

Primary: Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12 — 0.5; -32.6 Square Centimeter (cm^2) — p=<0.001

EMD Serono Results Jul 2018 2.0% serious AE View details

Phase 3 N=100 Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps

Chronic Sinusitis · Nasal Polyps

Primary: Nasal Obstruction/Congestion Score — 3.62; 3.30; 2.31; 2.62 units on a scale — p=0.1365

Intersect ENT Results Jul 2018 1.0% serious AE View details

Phase 3 N=80 Japanese IP-TN Trial

Pain

Primary: Percentage of Patients With Drug-related Adverse Events [AEs] — 7.5 Percentage of participants

Boehringer Ingelheim Results Jul 2018 0.0% serious AE View details

Phase 3 N=120 Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Epilepsy · Dravet Syndrome

Primary: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period — -38.94; -13.29 percent change — p=0.0123

Jazz Pharmaceuticals Results Jul 2018 10.8% serious AE View details

Phase 3 N=173 A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

Chronic Renal Failure Requiring Hemodialysis

Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1 — 17.4 Percentage of participants

Pfizer Results Jul 2018 34.7% serious AE View details